共查询到20条相似文献,搜索用时 10 毫秒
1.
Inhibition of platelet activation by the Alzheimer's disease amyloid precursor protein 总被引:3,自引:0,他引:3
Anna Henry Qiao-Xin LI Denise Galatis Lars Hesse Gerd Multhaup Konrad Beyreuther Colin L. Masters & Roberto Cappai 《British journal of haematology》1998,103(2):402-415
The amyloid precursor protein (APP) of Alzheimer's disease is abundantly expressed in the platelet α-granule where its role remains unclear. This study describes a novel function for APP in regulating human platelet activation. Preincubation of platelet-rich plasma with recombinant secreted APP (sAPP) isoforms dose-dependently inhibited platelet aggregation and secretion induced by ADP or adrenaline. Similarly, sAPP potently inhibited low-dose thrombin-induced activation in washed platelet suspensions, indicating that the activity does not require plasma cofactors. There were no functional differences between sAPP forms with or without the Kunitz protease inhibitor domain or derived from either α- or β-secretase cleavage. In fact, the N-terminal cysteine-rich region of APP (residues 18–194) was as effective as the entire sAPP region in the inhibition of platelet activation. The inhibitory activity of sAPP correlated with a significant reduction in the agonist-induced production of the arachidonic acid (AA) metabolites thromboxane B2 and prostaglandin E2 . However, sAPP did not affect AA-induced platelet aggregation or secretion, indicating the enzymatic conversion of AA was not inhibited. The addition of a threshold dose of AA reversed the sAPP-inhibition of agonist-induced platelet activation. This suggests that sAPP decreases the availability of free AA, although the mechanism is not yet known. These data provide evidence that the release of sAPP upon platelet degranulation may result in negative feedback regulation during platelet activation. 相似文献
2.
Suh YH Choi W Kim SH Kim JS Rhi BY Chong YH Woo JI Lee KW 《Archives of gerontology and geriatrics》1997,24(1):1-7
Beta-amyloid precursor protein (betaAPP) has been shown to be involved in cell growth regulation. In spleen, the majority of cells showing betaAPP like immunoreactivity was found in the T cell-dependent zone. In Northern blot, the expression of betaAPP was increased to reach the peak at 72 h after the treatment of phytohemagglutinin (PHA). But, in cytofluorometry, almost all CD4(+) T helper/inducer cells and the majority of CD(8+) T suppressor/cytotoxic cells show betaAPP immunoreactivity which remained constant during the stimulation with PHA. These results suggest that betaAPP is a surface molecule of T lymphocyte and the turnover or release of APP might be increased with the treatment of T cell mitogen. 相似文献
3.
目的探讨朊蛋白基因(PRNP)129密码子多态性与阿尔茨海默病(AD)的关联性。方法以AD组和健康对照组基因型分布的OR值为统计量进行荟萃。全面检索相关文献并应用Review Manager 4.2软件对各研究结果进行一致性检验和数据合并。结果4个相关文献结果差异无统计学意义。研究共包括AD组1095例,健康对照组940例,校正后包括3个研究AD组972例,健康对照658例。携带至少一个缬氨酸等位基因(V^*)的基因型相对于甲硫氨酸纯合子(MM)(即V^*/MM的合并,OR为0.80,95%C10.65—0.98,P=0.03)。携带至少一个甲硫氨酸等位基因(M^*)的基因型相对于缬氨酸纯合子(VV),即M^*/VV的合并(OR为1.38,95%CI1.01—1.89,P=0.04)。纯合子基因型相对于杂合子,即(MM+VV)/MV的合并(OR为1.10.95%C10.89—1.35,P=0.38)。结论欧洲人群PRNP129密码子纯合子发生AD的危险性增高,但无统计学意义。MM纯合子AD风险增加,M^*基因型与AD发病风险增加有关联,V^*基因型与AD发病风险减少有关联。 相似文献
4.
Parkin ET Watt NT Hussain I Eckman EA Eckman CB Manson JC Baybutt HN Turner AJ Hooper NM 《Proceedings of the National Academy of Sciences of the United States of America》2007,104(26):11062-11067
Proteolytic processing of the amyloid precursor protein (APP) by beta-secretase, beta-site APP cleaving enzyme (BACE1), is the initial step in the production of the amyloid beta (Abeta) peptide, which is involved in the pathogenesis of Alzheimer's disease. The normal cellular function of the prion protein (PrP(C)), the causative agent of the transmissible spongiform encephalopathies such as Creutzfeldt-Jakob disease in humans, remains enigmatic. Because both APP and PrP(C) are subject to proteolytic processing by the same zinc metalloproteases, we tested the involvement of PrP(C) in the proteolytic processing of APP. Cellular overexpression of PrP(C) inhibited the beta-secretase cleavage of APP and reduced Abeta formation. Conversely, depletion of PrP(C) in mouse N2a cells by siRNA led to an increase in Abeta peptides secreted into the medium. In the brains of PrP knockout mice and in the brains from two strains of scrapie-infected mice, Abeta levels were significantly increased. Two mutants of PrP, PG14 and A116V, that are associated with familial human prion diseases failed to inhibit the beta-secretase cleavage of APP. Using constructs of PrP, we show that this regulatory effect of PrP(C) on the beta-secretase cleavage of APP required the localization of PrP(C) to cholesterol-rich lipid rafts and was mediated by the N-terminal polybasic region of PrP(C) via interaction with glycosaminoglycans. In conclusion, this is a mechanism by which the cellular production of the neurotoxic Abeta is regulated by PrP(C) and may have implications for both Alzheimer's and prion diseases. 相似文献
5.
K Nagano T Miki K Yoshioka D Katsumi T Katsuya M Takeda M Ikeda H Tanabe T Nishimura Y Sakai 《Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics》1992,29(6):509-514
Numerous Caucasian familial Alzheimer's disease (FAD) pedigrees have been described in the literature, while only 21 Japanese FAD families have been reported to date. Here we report the clinical findings and the result of molecular genetic analysis of 4 patients from two FAD kindreds, OS-2 and OS-3. The proband in OS-2 family has developed loss of recent memory and place disorientation age at 43. A brain CT showed severe diffuse cortical atrophy. Her younger brother had dementia at 42 years and her mother and other 3 siblings had also dementia symptoms suspected to be Alzheimer's disease. The proband in OS-3 family showed declining recent memory at 49 years and developed dysphagia, gait disturbance and emotional incontinent with cerebral atrophy at 52 years. His father and elder brother demonstrated dementia signs at 60 and 54 years old, respectively. Recently it was reported that affected members from 2 Caucasian kindreds with FAD had missense mutation in exon 17 of the gene for amyloid precursor protein (APP). Patients from three different Japanese kindreds with FAD also showed the same mutation on the APP gene. Amino acid substitution (Val-Ile) at codon 717 by this mutation is responsible for FAD in at least some kindreds. We used genomic DNA from 4 affected members of 2 families to determine whether the disease in these families is associated with a APP717 mutation and the mutated codons, 102, 117, 129, 178 and 200, on the gene for protease-resistance prion protein (PrP) which cause transmissible dementia, Creutzfelt-Jacob disease (CJD) and Gerstmann-Strausler syndrome (GSS).(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
6.
A unique gene expression signature discriminates familial Alzheimer's disease mutation carriers from their wild-type siblings
下载免费PDF全文
![点击此处可从《Proceedings of the National Academy of Sciences of the United States of America》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Nagasaka Y Dillner K Ebise H Teramoto R Nakagawa H Lilius L Axelman K Forsell C Ito A Winblad B Kimura T Graff C 《Proceedings of the National Academy of Sciences of the United States of America》2005,102(41):14854-14859
Alzheimer's disease (AD) is a neurodegenerative disease with an insidious onset and progressive course that inevitably leads to death. The current diagnostic tools do not allow for diagnosis until the disease has lead to irreversible brain damage. Genetic studies of autosomal dominant early onset familial AD has identified three causative genes: amyloid precursor protein (APP), presenilin 1 and 2 (PSEN1 and PSEN2). We performed a global gene expression analysis on fibroblasts from 33 individuals (both healthy and demented mutation carriers as well as wild-type siblings) from three families segregating the APP(SWE), APP(ARC) and PSEN1 H163Y mutations, respectively. The mutations cause hereditary progressive cognitive disorder, including typical autosomal dominant AD. Our data show that the mutation carriers share a common gene expression profile significantly different from that of their wild-type siblings. The results indicate that the disease process starts several decades before the onset of cognitive decline, suggesting that presymptomatic diagnosis of AD and other progressive cognitive disorders may be feasible in the near future. 相似文献
7.
Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease 总被引:7,自引:0,他引:7
下载免费PDF全文
![点击此处可从《Proceedings of the National Academy of Sciences of the United States of America》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Monsonego A Maron R Zota V Selkoe DJ Weiner HL 《Proceedings of the National Academy of Sciences of the United States of America》2001,98(18):10273-10278
Alzheimer's disease is a dementia that involves progressive deposition of amyloid beta-protein (Abeta) in brain regions important for memory and cognition, followed by secondary inflammation that contributes to the neuropathologic process. Immunization with Abeta can reduce cerebral Abeta burden and consequent neuropathologic changes in the brains of mice transgenic for the beta-amyloid precursor protein (APP). We found that transgenic expression of human APP in B6SJL mice, under the prion promoter, results in immune hyporesponsiveness to human Abeta, in terms of both antibody and cellular immune responses. The decreased antibody responses were related not to B cell tolerance but rather to the inability of Abeta-specific T cells to provide help for antibody production. The immune hyporesponsiveness could be overcome if T cell help was provided by coupling an Abeta B cell epitope to BSA. Our results suggest that expression of APP in transgenic mice is associated with an Abeta-specific impaired adaptive immune response that may contribute to the neuropathology. Moreover, humans with life-long elevation of brain and peripheral Abeta (e.g., patients with presenilin mutations or Down syndrome) could have reduced immune responses to Abeta vaccination. 相似文献
8.
目的探讨Desmin基因exon6的A360P错义突变与克山病心肌损伤发生发展的关系。方法采用临床流行病学方法调查,随机抽取年龄、性别相匹配的慢型和潜在型克山病患者,病区正常组和非病区正常组各30例的血样,提取基因组DNA,采用PCR扩增、酶切,电泳等技术比较各组Desmin基因片断酶切位点的变化。结果慢型和潜在型克山病患者与病区正常组未检出Desmin基因exon6的A360P错义突变错义突变位点。结论Desmin基因exon6的A360P错义突变可能不是克山病心肌损伤的易感基因突变。 相似文献
9.
The molecular basis of hemoglobin H disease in a Black family of Canadian origin was investigated. Affected individuals had a combination of deletion and nondeletion alpha-thalassemia mutations on different chromosomes. Cloning and sequencing of the DNA of one member with the nondeletion form revealed a new thalassemia mutation, an A---- G substitution, in the initiation codon of the remaining alpha-globin gene of a rightward (-alpha 3.7) deletion chromosome. This mutation abolished an Ncol restriction site and therefore is detectable in genomic DNA by Southern blot analysis. 相似文献
10.
P Cras M Kawai D Lowery P Gonzalez-DeWhitt B Greenberg G Perry 《Proceedings of the National Academy of Sciences of the United States of America》1991,88(17):7552-7556
Senile plaques are polymorphous beta-amyloid protein deposits found in the brain in Alzheimer disease and normal aging. This beta-amyloid protein is derived from a larger precursor molecule of which neurons are the principal producers in brain. We found that amyloid precursor protein (APP)-immunoreactive neurites were involved in senile plaques and that only a subset of these neurites showed markers for the abnormal filaments characteristic of neurofibrillary pathology. In the neocortex of nondemented individuals with senile plaques but spared of neurofibrillary pathology, dystrophic neurites in senile plaques showed only APP accumulation. In contrast, in the brains of Alzheimer patients, virtually all APP-immunoreactive neurites also showed immunoreactivity with ubiquitin, tau, and phosphorylated neurofilaments. The presence of tau and neurofilament epitopes in dystrophic neurites in senile plaques was correlated with the extent of neurofibrillary pathology in the surrounding brain tissue. Accumulation of APP and the formation of neurofibrillary pathology in senile plaque neurites are therefore distinct phenomena. Our findings suggest that APP accumulation in senile plaque neurites occurs prior to tau accumulation and is therefore more closely related to appearance of neuritic dystrophy. 相似文献
11.
Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease 总被引:25,自引:0,他引:25
Lammich S Kojro E Postina R Gilbert S Pfeiffer R Jasionowski M Haass C Fahrenholz F 《Proceedings of the National Academy of Sciences of the United States of America》1999,96(7):3922-3927
Amyloid beta peptide (Abeta), the principal proteinaceous component of amyloid plaques in brains of Alzheimer's disease patients, is derived by proteolytic cleavage of the amyloid precursor protein (APP). Proteolytic cleavage of APP by a putative alpha-secretase within the Abeta sequence precludes the formation of the amyloidogenic peptides and leads to the release of soluble APPsalpha into the medium. By overexpression of a disintegrin and metalloprotease (ADAM), classified as ADAM 10, in HEK 293 cells, basal and protein kinase C-stimulated alpha-secretase activity was increased severalfold. The proteolytically activated form of ADAM 10 was localized by cell surface biotinylation in the plasma membrane, but the majority of the proenzyme was found in the Golgi. These results support the view that APP is cleaved both at the cell surface and along the secretory pathway. Endogenous alpha-secretase activity was inhibited by a dominant negative form of ADAM 10 with a point mutation in the zinc binding site. Studies with purified ADAM 10 and Abeta fragments confirm the correct alpha-secretase cleavage site and demonstrate a dependence on the substrate's conformation. Our results provide evidence that ADAM 10 has alpha-secretase activity and many properties expected for the proteolytic processing of APP. Increases of its expression and activity might be beneficial for the treatment of Alzheimer's disease. 相似文献
12.
13.
14.
Ghanim H Monte SV Sia CL Abuaysheh S Green K Caruana JA Dandona P 《The Journal of clinical endocrinology and metabolism》2012,97(7):E1197-E1201
15.
16.
IntroductionBeta-amyloid is considered to be a pathophysiological marker in Alzheimer's disease (AD). Soluble amyloid precursor proteins (sAPPs) –α (sAPPα) and –β (sAPPβ), which are the byproducts of non-amyloidogenic and amyloidogenic process of APP, respectively, have been repeatedly observed in the cerebrospinal fluids (CSF) of AD patients. The present study focused on the determination of sAPP levels in peripheral blood.MethodsThe plasma protein levels of sAPPα and sAPPβ were measured with ELISA. Plasma from 52 AD patients, 98 amnestic mild cognitive impairment (MCI) patients, and 114 cognitively normal controls were compared.ResultsThe plasma level of sAPPβ was significantly increased in AD patients than in cognitively healthy controls. However, no significant change in plasma sAPPα was observed among the three groups. Furthermore, the plasma sAPPβ levels significantly correlated with cognitive assessment scales, such as clinical dementia rating (CDR), and mini-mental status examination (MMSE). Interestingly, sAPPα and sAPPβ had a positive correlation with each other in blood plasma, similar to previous studies on CSF sAPP. This correlation was stronger in the MCI and AD groups than in the cognitively healthy controls.ConclusionsThese results suggest that individuals with elevated plasma sAPPβ levels are at an increased risk of AD; elevation in these levels may reflect the progression of disease. 相似文献
17.
目的 构建携带突变型人淀粉样前体蛋白基因(APP695)与增强型绿色荧光蛋白(EGFP)基因融合载体.方法 在NCBI上查找APP695的序列,设计引物.以pCB6质粒携带的野生型APP695序列为模板,以突变体引物扩增突变型APP695. 将突变型APP695与pIRES2-EGFP连接并测序证实.结果 经过酶切鉴定、PCR和DNA测序等方法,证实构建的pIRES2-EGFP/APP695突变型质粒载体序列正确.结论 成功构建APP695-EGFP融合基因载体,为研究AD发病的分子机制和治疗时的药物筛选奠定基础. 相似文献
18.
Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease 总被引:11,自引:0,他引:11
下载免费PDF全文
![点击此处可从《Proceedings of the National Academy of Sciences of the United States of America》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Bales KR Verina T Cummins DJ Du Y Dodel RC Saura J Fishman CE DeLong CA Piccardo P Petegnief V Ghetti B Paul SM 《Proceedings of the National Academy of Sciences of the United States of America》1999,96(26):15233-15238
19.
Ancolio K Dumanchin C Barelli H Warter JM Brice A Campion D Frébourg T Checler F 《Proceedings of the National Academy of Sciences of the United States of America》1999,96(7):4119-4124
We have identified a novel beta amyloid precursor protein (betaAPP) mutation (V715M-betaAPP770) that cosegregates with early-onset Alzheimer's disease (AD) in a pedigree. Unlike other familial AD-linked betaAPP mutations reported to date, overexpression of V715M-betaAPP in human HEK293 cells and murine neurons reduces total Abeta production and increases the recovery of the physiologically secreted product, APPalpha. V715M-betaAPP significantly reduces Abeta40 secretion without affecting Abeta42 production in HEK293 cells. However, a marked increase in N-terminally truncated Abeta ending at position 42 (x-42Abeta) is observed, whereas its counterpart x-40Abeta is not affected. These results suggest that, in some cases, familial AD may be associated with a reduction in the overall production of Abeta but may be caused by increased production of truncated forms of Abeta ending at the 42 position. 相似文献
20.
《Haematologica》2014,99(10):e201-e204